Annual report
150A.TEDINET S100W21B
Period2024-04-01 → 2025-03-31
Filed2025-06-23
StandardJapan GAAP
ConsolidatedYes
Data checks17 of 17 passed
Amended by S100YDX1 (2026-06-18).
Key figures · 98
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Operating income | ¥176m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥185m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥180m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥144m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥144m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥3.0bn | at 2025-03-31 | Cons. | Assets |
| Total liabilities | ¥944m | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.0bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.8bn | at 2024-03-31 | Cons. | Net assets |
| Cash and deposits | ¥811m | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥811m | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥138m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥691m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥168m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥25.67 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥25.22 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥362.46 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 68.3% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 7.1% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 488 | at 2025-03-31 | Cons. | Number of employees |
| Revenue | ¥4.0bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥3.5bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥3.0bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.3bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥186m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥208m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥194m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥195m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥161m | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥83m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥143m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥189m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥195m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥153m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥145m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥188m | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥61m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥142m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.9bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥2.5bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥2.0bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.6bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥881m | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥889m | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥705m | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.0bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.8bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.3bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥663m | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥84m | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥774m | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.2bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.2bn | at 2024-03-31 | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥803m | at 2023-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥680m | at 2022-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥300m | 2023-04-01 → 2024-03-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥225m | 2022-04-01 → 2023-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥145m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥117m | 2023-04-01 → 2024-03-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥195m | 2022-04-01 → 2023-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥176m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥211m | 2023-04-01 → 2024-03-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥94m | 2022-04-01 → 2023-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥486m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥27.33 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.29 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.25 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.33 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7,203.3 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥26.85 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥31.27 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥364.07 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥334.63 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥-258.78 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥-352.71 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥-70,217.77 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 69.7% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.2% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.9% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.2% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 9.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 7.9% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 18.8% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.3% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 5,624,100 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,482,600 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 10,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 10,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 10,200 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 484 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 427 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 383 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 301 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 216 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 43
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 4 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥5m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥46m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥2m |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥6m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥1m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥957m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥545m |
| Home Care Medicine Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥822,000 |
| Home Care Medicine Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥4m |
| Home Care Medicine Businessreportable segment | employees | at 2025-03-31 | 184 pure |
| Home Care Medicine Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.5bn |
| Home Care Medicine Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.5bn |
| Home Care Medicine Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥390,000 |
| Home Care Medicine Businessreportable segment | segment assets | at 2025-03-31 | ¥295m |
| Home Care Medicine Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥165m |
| Regional Revitalization Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥803m |
| Regional Revitalization Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥139m |
| Regional Revitalization Businessreportable segment | employees | at 2025-03-31 | 273 pure |
| Regional Revitalization Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.5bn |
| Regional Revitalization Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.5bn |
| Regional Revitalization Businessreportable segment | segment assets | at 2025-03-31 | ¥1.7bn |
| Regional Revitalization Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥555m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥804m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥143m |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥4.0bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥4.0bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥390,000 |
| —segment total | segment assets | at 2025-03-31 | ¥2.0bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥720m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥804m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥143m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥4.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥4.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥721m |
| Home Care Medicine Businessreportable segment | employees | at 2025-03-31 | 184 pure |
| Regional Revitalization Businessreportable segment | employees | at 2025-03-31 | 273 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,281
| Item | Context | Value | Unit |
|---|---|---|---|
| Other net fin cf | CurrentYearDuration | -2089000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | 167650000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | -386019000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 1196843000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 810824000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 1 | |
| Accumulated depreciation ppe by group | CurrentYearInstant | -404820000 | JPY |
| Directors compensations sga | CurrentYearDuration | 202740000 | JPY |
| Salaries and allowances sga | CurrentYearDuration | 375111000 | JPY |
| Provision for bonuses sga | CurrentYearDuration | 9280000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration | 2078000 | JPY |
| Legal welfare expenses sga | CurrentYearDuration | 76511000 | JPY |
| Advertising expenses sga | CurrentYearDuration | 172530000 | JPY |
| Commission fee sga | CurrentYearDuration | 129427000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYearDuration | 1192000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E39184-000RegionalRevitalizationBusinessReportableSegmentMember | 2508781000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E39184-000HomeCareMedicineBusinessReportableSegmentMember | 1454225000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReportableSegmentsMember | 3963006000 | JPY |
| Revenues from external customers | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4000000 | JPY |
| Revenues from external customers | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 3967006000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYearDuration | 3967006000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E39184-000RegionalRevitalizationBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E39184-000HomeCareMedicineBusinessReportableSegmentMember | 390000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReportableSegmentsMember | 390000 | JPY |
| Transactions with other segments | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1000000 | JPY |
| Transactions with other segments | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 1390000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReconcilingItemsMember | -1390000 | JPY |
| Transactions with other segments | CurrentYearDuration | － | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E39184-000RegionalRevitalizationBusinessReportableSegmentMember | 2508781000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E39184-000HomeCareMedicineBusinessReportableSegmentMember | 1454615000 | JPY |
| Net sales | CurrentYearDuration_ReportableSegmentsMember | 3963396000 | JPY |
| Net sales | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 5000000 | JPY |
| Net sales | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 3968396000 | JPY |
| Net sales | CurrentYearDuration_ReconcilingItemsMember | -1390000 | JPY |
| Net sales | CurrentYearDuration | 3967006000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E39184-000RegionalRevitalizationBusinessReportableSegmentMember | 555026000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E39184-000HomeCareMedicineBusinessReportableSegmentMember | 164516000 | JPY |
| Operating income | CurrentYearDuration_ReportableSegmentsMember | 719542000 | JPY |
| Operating income | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1868000 | JPY |
| Operating income | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 721411000 | JPY |
| Operating income | CurrentYearDuration_ReconcilingItemsMember | -545132000 | JPY |
| Operating income | CurrentYearDuration | 176278000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E39184-000RegionalRevitalizationBusinessReportableSegmentMember | 1684442000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E39184-000HomeCareMedicineBusinessReportableSegmentMember | 295062000 | JPY |
| Assets | CurrentYearInstant_ReportableSegmentsMember | 1979505000 | JPY |
| Assets | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 46490000 | JPY |
| Assets | CurrentYearInstant_TotalOfReportableSegmentsAndOthersMember | 2025995000 | JPY |
| Assets | CurrentYearInstant_ReconcilingItemsMember | 956606000 | JPY |
| Assets | CurrentYearInstant | 2982602000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 17 of 17 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |